1,25-Dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: A pilot feasibility study

Journal of Steroid Biochemistry and Molecular Biology

Volumn 121, Issue 1-2, 2010, Pages 445-447

  Judd, Suzanne E ^a   Raiser, Sara N ^b   Kumari, Meena ^b   Tangpricha, Vin ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure treatment; Calcitriol; Cholecalciferol; Hypertension; Renin; Vitamin D

Indexed keywords

CALCITRIOL; COLECALCIFEROL; PLACEBO; BIOLOGICAL MARKER; RENIN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HYPERTENSION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; AFRICAN AMERICAN; BLOOD PRESSURE; DRUG EFFECTS; ETHNOLOGY; FEASIBILITY STUDY; METABOLISM; MIDDLE AGED; SYSTOLE;

ADULT; AFRICAN AMERICANS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCITRIOL; CHOLECALCIFEROL; FEASIBILITY STUDIES; HUMANS; HYPERTENSION; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; RENIN; SYSTOLE;

EID: 77954761811     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.04.013     Document Type: Article

References (19)

1. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham study. Am. J. Hypertens. 2000, 13:03S.
2. Elias M.F., Wolf P.A., D'Agostino R.B., Cobb J., White L.R. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study. Am. J. Epidemiol. 1993, 138:353-364.
3. Scragg R., Sowers M., Bell C., et al. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004, 27:2813-2818.
4. Judd S.E, Nanes M.S., Ziegler T.R., Wilson P.W., Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutrition 2008, 87:136-141.
5. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O.H., Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 1995, 8:894-901.
6. Kristal-Boneh E., Froom P., Harari G., Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997, 30:1289-1294.
7. Pfeifer M., Begerow B., Minne H.W., Nachtigall D., Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 2001, 86:1633-1637.
8. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutrition 2006, 83:754-759.
9. Hsia J., Heiss G., Ren H., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115(7):846-854.
10. Forman J.P., Giovannucci E., Holmes M.D., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
11. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
12. Li Y.C., Qiao G., Uskokovic M., Xiang W., Zheng W., Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol. 2004, 89-90:387-392.
13. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
14. Kimura Y., Kawamura M., Owada M., et al. Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern. Med. 1999, 38:31-35.
15. 3 modifies growth and contractile function of vascular smooth muscle of spontaneously hypertensive rats. Am. J. Hypertens. 1989, 2:553-556.
16. 3 modulates growth of vascular smooth muscle cells. J. Clin. Invest. 1991, 87:1889.
17. 3-1a-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Am. Heart Assoc. 2005, 1666-1671.
18. 3 works as anti-inflammatory. Diabetes Res. Clin. Pract. 2007, 77:47-57.
19. Harrison D.G., Cai H., Landmesser U., Griendling K.K. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J. Renin Angiot. Aldosterone Syst. 2003, 4:51-61.